Department of Gastroenterology, Nippon Medical School, Graduate School of Medicine, 1-1-5 Sendagi, Bunkyo-ku, Tokyo, 113-8603, Japan.
Department of Gastroenterological Endoscopy, Tokyo Medical University, Tokyo, Japan.
J Gastroenterol. 2024 Jan;59(1):24-33. doi: 10.1007/s00535-023-02057-9. Epub 2023 Nov 25.
Current evidence on the surgical rate, indication, procedure, risk factors, mortality, and postoperative rebleeding for acute lower gastrointestinal bleeding (ALGIB) is limited.
We constructed a retrospective cohort of 10,342 patients admitted for acute hematochezia at 49 hospitals (CODE BLUE J-Study) and evaluated clinical data on the surgeries performed.
Surgery was performed in 1.3% (136/10342) of the cohort with high rates of colonoscopy (87.7%) and endoscopic hemostasis (26.7%). Indications for surgery included colonic diverticular bleeding (24%), colorectal cancer (22%), and small bowel bleeding (16%). Sixty-four percent of surgeries were for hemostasis for severe refractory bleeding. Postoperative rebleeding rates were 22% in patients with presumptive or obscure preoperative identification of the bleeding source and 12% in those with definitive identification. Thirty-day mortality rates were 1.5% and 0.8% in patients with and without surgery, respectively. Multivariate analysis showed that surgery-related risk factors were transfusion need ≥ 6 units (P < 0.001), in-hospital rebleeding (P < 0.001), small bowel bleeding (P < 0.001), colorectal cancer (P < 0.001), and hemorrhoids (P < 0.001). Endoscopic hemostasis was negatively associated with surgery (P = 0.003). For small bowel bleeding, the surgery rate was significantly lower in patients with endoscopic hemostasis as 2% compared to 12% without endoscopic hemostasis.
Our cohort study elucidated the outcomes and risks of the surgery. Extensive exploration including the small bowel to identify the source of bleeding and endoscopic hemostasis may reduce unnecessary surgery and improve the management of ALGIB.
目前关于急性下消化道出血(ALGIB)的手术率、适应证、手术方式、危险因素、死亡率和术后再出血的证据有限。
我们构建了一个由 49 家医院收治的 10342 例急性血便患者组成的回顾性队列(CODE BLUE J-Study),并评估了手术相关的临床数据。
该队列中有 1.3%(136/10342)的患者接受了手术,结肠镜检查率较高(87.7%),内镜止血率为 26.7%。手术适应证包括结肠憩室出血(24%)、结直肠癌(22%)和小肠出血(16%)。64%的手术是为了治疗严重难治性出血进行止血。有术前疑似或不明原因出血源的患者术后再出血率为 22%,而有明确出血源的患者为 12%。手术组和非手术组的 30 天死亡率分别为 1.5%和 0.8%。多变量分析显示,与手术相关的危险因素包括需要输血≥6 单位(P<0.001)、住院期间再出血(P<0.001)、小肠出血(P<0.001)、结直肠癌(P<0.001)和痔疮(P<0.001)。内镜止血与手术呈负相关(P=0.003)。对于小肠出血,有内镜止血的患者手术率明显低于无内镜止血的患者(2%比 12%)。
本队列研究阐明了手术的结果和风险。广泛探查包括小肠以确定出血源,并进行内镜止血,可能减少不必要的手术,并改善 ALGIB 的治疗。